Raheem Amr Abdel, Kell Philip
St. Peter's Andrology Department, The Institute of Urology, London, and Cairo University, Egypt;
Patient Prefer Adherence. 2009 Nov 3;3:99-104. doi: 10.2147/ppa.s3349.
Erectile dysfunction (ED) is a problem that may affect up to 52% of men between the ages of 40 and 70. It can be distressing because of its negative effect on self-esteem, quality of life, and interpersonal relationships. Oral phosphodiesterase-5 inhibitors (PDE5 inhibitors) are now the first choice of treatment in ED. The availability of three (sildenafil citrate, tadalafil, and vardenafil) well tolerated and effective oral PDE5 inhibitors gives treatment options for men with ED. Although the mechanism of action is the same for the three drugs, they differ in their pharmacokinetics. Several preference studies were conducted between the three PDE5 inhibitors but they were not free from bias. Because of the lack of overwhelming reliable data showing that one PDE5 inhibitor is superior to another, current opinion is that the individual patient should have the opportunity to test all three drugs and then select the one that best suits him and his partner.
勃起功能障碍（ED）是一个可能影响高达52%的40至70岁男性的问题。由于其对自尊、生活质量和人际关系的负面影响，它可能令人苦恼。口服磷酸二酯酶-5抑制剂（PDE5抑制剂）现在是ED治疗的首选。三种耐受性良好且有效的口服PDE5抑制剂（枸橼酸西地那非、他达拉非和伐地那非）的可获得性为患有ED的男性提供了治疗选择。尽管这三种药物的作用机制相同，但它们的药代动力学有所不同。在这三种PDE5抑制剂之间进行了几项偏好研究，但这些研究并非没有偏差。由于缺乏压倒性的可靠数据表明一种PDE5抑制剂优于另一种，目前的观点是个体患者应有机会试用所有三种药物，然后选择最适合他和他伴侣的那种。
